SENS - Senseonics Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
4.02
+0.15 (+3.88%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.87
Open3.90
Bid0.00 x 0
Ask0.00 x 0
Day's Range3.88 - 4.03
52 Week Range2.15 - 5.29
Volume1,339,626
Avg. Volume1,975,822
Market Cap704.774M
Beta-0.38
PE Ratio (TTM)N/A
EPS (TTM)-0.54
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.92
Trade prices are not sourced from all markets
  • Business Wire12 days ago

    Senseonics & Glooko Announce Partnership on Integrated Diabetes Management

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced a partnership with Glooko, Inc, the leading diabetes data management company. The partnership enables integration of the long-term Eversense® branded continuous glucose monitoring (CGM) systems with Glooko’s diabetes data management platform.

  • Why Senseonics Holdings Is Up ~5.6% Today
    Market Realist19 days ago

    Why Senseonics Holdings Is Up ~5.6% Today

    Today, Senseonics Holdings (SENS) is trading higher than yesterday’s close of $4.43 per share. The stock was up ~5% in premarket trading and is trending higher since then. SENS stock registered a 52-week high of $5.29 on June 22, as the company received FDA pre-market approval for the sale of its Eversense CGM (continuous glucose monitoring) system, which is the first CGM with implantable sensor and continuous monitoring capability for up to three months.

  • 3 Best Diabetes Stocks of 2018 So Far
    Motley Fool19 days ago

    3 Best Diabetes Stocks of 2018 So Far

    These diabetes stocks gained at least 50% in the first half of the year. But can the momentum continue?

  • Implied Volatility Surging for Senseonics (SENS) Stock Options
    Zacks20 days ago

    Implied Volatility Surging for Senseonics (SENS) Stock Options

    Senseonics (SENS) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Business Wire24 days ago

    Senseonics Announces Closing of Public Offering of Common Stock

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares. Senseonics’ Eversense System is a long-term, implantable device, which includes a small sensor, smart transmitter and mobile application.

  • Business Wire26 days ago

    Senseonics Announces Pricing of Public Offering of Common Stock

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of a registered underwritten public offering of its common stock for proceeds of $130.0 million, before deducting estimated offering expenses payable by Senseonics. In addition, Senseonics has granted the underwriter a 30-day option to purchase up to an additional $19.5 million of shares of its common stock. A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was declared effective by the Securities and Exchange Commission (SEC) on April 19, 2018.

  • Business Wire27 days ago

    Senseonics Announces Public Offering of Common Stock

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it has commenced a registered underwritten public offering of $80 million of its shares of common stock. In addition, Senseonics has granted the underwriter a 30-day option to purchase up to an additional $12 million of its shares of common stock. All of the shares to be sold in the offering are to be sold by Senseonics.

  • Senseonics Launches the “Ever Mobile Clinic” – A Converted 18 Wheeler Training Facility to Tour United States
    Business Wire27 days ago

    Senseonics Launches the “Ever Mobile Clinic” – A Converted 18 Wheeler Training Facility to Tour United States

    Senseonics Holdings, Inc. (NYSE American: SENS) today announced the launch of the company’s Ever Mobile Clinic Tour, a program to bring hands-on diabetes device training and education directly to U.S. patients and healthcare professionals in their local areas via a custom-built 18-wheeler mobile training facility. The national education-based tour features the Ever Mobile Clinic, a mobile educational facility custom-built within a semi-truck to accommodate the education and training of healthcare professionals and patients in the use of the company’s recently approved Eversense® Continuous Glucose Monitoring (CGM) System.

  • Business Wire27 days ago

    Six-Month Data on Long-Term Eversense CGM System Show Sustained Accuracy in Longest Pediatric Continuous Sensor Study

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced the presentation by third party researchers of new data from a clinical study evaluating the performance of the Eversense® XL Continuous Glucose Monitoring (CGM) system for up to 180 days in pediatrics and adults with diabetes. Findings were presented on June 22, 2018 at the American Diabetes Association’s (ADA) 78th Scientific Sessions. “This is the first study to examine any CGM system in a pediatric population for a period of continuous wear for more than 14 days,” said Dr. Ronnie Aronson, MD, FRCPC, FACE, primary investigator, endocrinologist and chief medical officer of LMC Diabetes & Endocrinology, Toronto, Canada.

  • ACCESSWIRE27 days ago

    Complimentary Technical Snapshots on Senseonics Holdings and Three More Medical Equipment Stocks

    Stock Research Monitor: EW, PBH, and VAR LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on SENS sign up now at www.wallstequities.com/registration . On Friday, June 22, 2018, ...

  • GlobeNewswirelast month

    Heico, MSG Networks, WageWorks, and Ingredion — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, June 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Senseonics ...

  • MarketWatchlast month

    FDA approves first implantable glucose monitor

    MARKET PULSE The Food and Drug Administration on Thursday approved the first implantable glucose monitoring system for diabetics, a product made by Senseonics Holdings Inc. (sens) The system requires a small sensor to be surgically implanted in an outpatient procedure; the sensor uses light readings to relay blood-sugar levels to a mobile app for 90 days.

  • PR Newswirelast month

    FDA Approves World's First Long-Term Implantable Continuous Glucose Monitoring System for Marketing in United States

    GERMANTOWN, Md., June 21, 2018 /PRNewswire/ -- Senseonics Holdings, Inc. (NYSE American: SENS) today announced the U.S. Food and Drug Administration has approved its Premarket Approval (PMA) application to market the company's Eversense® Continuous Glucose Monitoring (CGM) System to people with diabetes in the United States. The system is the first and only CGM system to feature an implantable glucose sensor and provide long-term continuous monitoring for up to three months. "We're very pleased to receive this FDA approval that allows us to make Eversense available in the United States, as it is in many European markets.  With the parallel trends of wearable personal devices and medical implantables for people to manage their health, this product exemplifies the natural evolution for diabetes devices, and Senseonics is excited to help lead the way," said Tim Goodnow, President and CEO of Senseonics.

  • Business Wirelast month

    Senseonics and Beta Bionics Partner on Development of the Bionic Pancreas System

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, a medical technology company leveraging machine learning artificial intelligence to develop and commercialize the world’s first autonomous bionic pancreas, today announced that they have entered into a development agreement to integrate glucose data from the Eversense® Continuous Glucose Monitoring (CGM) system into the iLet Bionic Pancreas system. The Eversense CGM system is a long-term, implantable continuous glucose monitoring system that continually measures interstitial fluid glucose levels and wirelessly sends the readings to a smartphone application.

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Prestige Brands and Three More Medical Equipment Stocks

    Stock Research Monitor: EYES, SENS, and VAR LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on PBH sign up now at www.wallstequities.com/registration . Ahead of today's trading ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SENS earnings conference call or presentation 10-May-18 8:30pm GMT

    Q1 2018 Senseonics Holdings Inc Earnings Call

  • 3 Top Stocks Under $5
    Motley Fool2 months ago

    3 Top Stocks Under $5

    These low-priced stocks could generate huge returns. But there are huge risks, too.

  • Associated Press2 months ago

    Senseonics: 1Q Earnings Snapshot

    The Germantown, Maryland-based company said it had a loss of 16 cents per share. The medical technology company posted revenue of $2.9 million in the period. In the final minutes of trading on Thursday, ...

  • Business Wire2 months ago

    Senseonics Holdings, Inc. Reports First Quarter 2018 Financial Results

    Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, today reported financial results for the first quarter ended March 31, 2018.

  • Business Wire2 months ago

    Senseonics to Participate in the UBS Global Healthcare Conference

    Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring system for people with diabetes, today announced the company plans to participate in the upcoming UBS Global Healthcare Conference in New York, NY.

  • GlobeNewswire3 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Sonic Automotive, STERIS plc, AquaVenture, Senseonics, Acceleron Pharma, and Steelcase — New Research Emphasizes Economic Growth

    NEW YORK, May 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sonic ...

  • Business Wire3 months ago

    Senseonics Holdings, Inc. Schedules First Quarter 2018 Earnings Release and Conference Call for May 10, 2018 at 4:30 p.m. Eastern Time

    Senseonics Holdings, Inc. today announced that it plans to release its first quarter 2018 financial results after market close on Thursday, May 10, 2018.

  • ACCESSWIRE3 months ago

    Free Post Earnings Research Report: Senseonics' Quarterly Revenues Zoomed 867%

    Stock Monitor: ReShape Lifesciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free earnings report on Senseonics Holdings, Inc. (NYSE: ...

  • Does Senseonics Holdings Inc’s (NYSEMKT:SENS) -34.53% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.3 months ago

    Does Senseonics Holdings Inc’s (NYSEMKT:SENS) -34.53% Earnings Drop Reflect A Longer Term Trend?

    Today I will take a look at Senseonics Holdings Inc’s (AMEX:SENS) most recent earnings update (31 December 2017) and compare these latest figures against its performance over the past fewRead More...

  • Senseonics Holdings (SENS) Jumps: Stock Rises 5.7%
    Zacks3 months ago

    Senseonics Holdings (SENS) Jumps: Stock Rises 5.7%

    Shares of Senseonics Holdings (SENS) rose nearly 6% yesterday.